Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Enterobacteriaceae Infections Escherichia Coli Infections Gram-Negative Bacterial Infections Infections Klebsiella Infections

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul, 133-792, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Eligible patients of either sex, 15 years of age or older
Patients who are admitted to the department of hematology and oncology
Provide written informed consent

Exclusion criteria

Patients who have hypersensitivity to β-lactam antibiotics
Female who are pregnant or breast-feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Treatment and study plan

Piperacillin-tazobactam

Drug

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Important dates

Study start: 2005
First posted: Sep 14, 2005
Registry last updated: Mar 15, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed